Skip to content

Development of Fluid Intake App for Management of Fluid Intake During Hemodialysis , Full Scale Trial

Fluid Intake App for Management of Volume Intake in Patients Receiving Chronic Hemodialysis Therapy, Full Scale Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04194164
Enrollment
33
Registered
2019-12-11
Start date
2019-12-02
Completion date
2021-11-01
Last updated
2022-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Weight Gain

Keywords

Hemodialysis, End stage renal disease on dialysis, Fluid intake, Interdialytic weight gain

Brief summary

Methods are needed to help decrease interdialytic weight gains in hemodialysis patients. One potential method for accomplishing this goal is to develop an app for smartphones that allow patients to track their fluid intake throughout the course of the day. NCT 03759847 was designed to test the safety and efficacy of this app. In this protocol, part of the same IRB number, patients with large interdialytic fluid gains (3.5% or greater) will use the app to to determine the association between the interdialytic weight gain and the fluid consumed as recorded by use of the app for each interdialytic period.

Detailed description

In this full scale study, the app will be used to try and influence fluid intake behavior in those patients who are identified to have large fluid weight gains, as defined by a greater than 4% increase in interdialytic weight. There will be two parts to the full scale trial. In the first part of the full scale study, denoted as the active phase, which will last for two months, study participants will be encouraged to use the app on a daily basis and will meet with the study coordinator on weeks 1, 2, 4, 6, and 8 to further assist the participant in decreasing fluid intake between dialysis sessions. In the second portion of the study, denoted as the passive phase, which will last for six months, the patient will use the app and meet with the study coordinator only when requested by the patient. The number of these sessions will be recorded. At the end of the six month passive phase, the participant will meet for the last time with the study coordinator. During each study visit, subjects will be asked to transfer the data from the App to the study coordinator via the data export function of the app.

Interventions

Monitor fluid intake and interdialytic weight gain in patients using the fluid app

Sponsors

Danone Global Research & Innovation Center
CollaboratorINDUSTRY
Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Comparison of interdialytic weight gain with fluid intake as recorded by fluid app

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject, upon briefing of the content of the present study, fully understanding and agreeing to its objective and having given written (dated and signed) informed consent form to take part in the study. * Adult chronic hemodialysis patient who is at least 18 years of age * Average interdialytic fluid gains of 3.5% or greater of body weight for both weekdays and weekends for a 30 day period * Availability of interdialytic weight gains for the 2 month period prior to enrollment into the study * Access to a smartphone for use of the app and comfort with using apps on a regular basis * Access to a smartphone running under either iOS or Android operating systems * Sufficient knowledge and understanding of the English language to use the application available only in English (US) language * Mental capacity to use and understand the fluid management app * Willingness to share intake data collected with the research team

Exclusion criteria

* Scheduled for a living related renal transplant in the next seven months * Hospitalization within 30 days of entry into the study * Current participation in a randomized clinical trial or in the exclusion period of another clinical trial * Vulnerable subjects defined as individuals whose willingness to volunteer in the clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.

Design outcomes

Primary

MeasureTime frameDescription
Mean intradialytic weight gainbetween baseline (pre-app) and the Active phase (months 1 and 2)Comparison of interdialytic weight change before and during use of the app

Secondary

MeasureTime frameDescription
25th percentile of intradialytic weight gainbetween baseline (pre-app) and the Active phase (months 1 and 2), between baseline (pre-app) and the Passive phase (month 3-8)
75th percentile of intradialytic weight gainbetween baseline (pre-app) and the Active phase (months 1 and 2), between baseline (pre-app) and the Passive phase (month 3-8)
Mean intradialytic weight gainbetween baseline (pre-app) and the Active phase (months 1 and 2), between baseline (pre-app) and the Passive phase (month 3-8)
Percentage of days of app usagethe Active phase (months 1 and 2), Passive phase (month 3 through month 8)
Number of patients who experienced at least 50% increase in fluid intake during app usethe Active phase (months 1 and 2), Passive phase (month 3 through month 8)Safety evaluation.
Number of days of app usagethe Active phase (months 1 and 2), Passive phase (month 3 through month 8)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026